Isomorphic Labs said on November 17, 2026, that it had closed a $5 billion Series C funding round co-led by Greenoaks and Sequoia Capital. Source Source
Andreessen Horowitz participated alongside other new investors, while Alphabet continued investing, according to Isomorphic. The company also named Thrive Capital, MGX, GV, CapitalG, Temasek and the UK Sovereign AI Fund as existing investors participating in the round. Its web announcement did not break down individual contributions. Source
Isomorphic says it is scaling its proprietary drug-design engine, IsoDDE, and its pipeline of potential medicines designed with AI. Source
Demis Hassabis described the mission as “Solve All Disease.” Not exactly a modest to-do list. He said the company aims to use AI to radically cut the time and cost of finding new medicines. Source
@maxjaderberg wrote that the company was founded on the conviction that AI can turn biology into a programmable science. “We are clearly seeing this play out internally with our models’ capabilities translating into new potential medicines for patients.” Source
The company’s web announcement and these posts contain no clinical results or quantified reductions in drug-discovery time or cost. Source Source Source
Comments